Sanofi, Regeneron ready to file cemiplimab
Sanofi and Regeneron are gearing up to file their experimental PD-1 inhibitor cemiplimab on both sides of the Atlantic following the drug’s success in clinical trials.
Read More
Tag: EMPOWER
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
